LEXINGTON, Mass., June 6, 2018 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies, cancer vaccines, and adoptive cell
therapies1, announced today that Jennifer Buell, Ph.D., Chief Communications and
External Affairs Officer at Agenus, will make a presentation and
host one-on-one meetings with investors at the Jefferies 2018
Global Healthcare Conference at the Grand Hyatt Hotel, New York, NY.
Details of the presentation are provided below:
Presentation Time and Location: Thursday,
Jun 7 at 4:30-4:55 PM EDT in
Ballroom to be followed by a breakout session at 5:00-05:25 PM EDT in Uris.
A live audio webcast will be accessible on the "Events &
Presentations" section of the Company's investor website at
www.agenusbio.com where a replay will also be available following
the presentation.
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support early phase
clinical programs. Agenus is headquartered in Lexington, MA. For more information,
please visit www.agenusbio.com; information that may be important
to investors will be routinely posted on our website.
About AgenTus Therapeutics, Inc.
AgenTus
Therapeutics, a subsidiary of Agenus, is a preclinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of breakthrough "living drugs" to advance
potential cures for cancer patients. AgenTus employs
naturally-derived and engineered receptors, specifically T cell
receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to
supercharge human immune effector cells to seek and destroy
cancer. AgenTus also aims to advance adoptive cell therapy
formats which would enable off-the-shelf living drugs.
AgenTus has locations in Lexington,
MA and Cambridge, UK.
For more information, please visit
www.agentustherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Agenus' upcoming
presentation. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our most
recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K
filed with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
1Through AgenTus Therapeutics, a subsidiary of
Agenus
View original content with
multimedia:http://www.prnewswire.com/news-releases/agenus-to-present-at-the-jefferies-2018-global-healthcare-conference-in-new-york-ny-300661018.html
SOURCE Agenus